Comprehensive Stock Comparison
Compare Aspire Biopharma Holdings, Inc. (ASBP) vs Nautilus Biotechnology, Inc. (NAUT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  ASBP | Beta 1.61 vs NAUT's 1.71 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  NAUT | +118.3% vs ASBP's +71.4% |
| Efficiency (ROA) | NAUT | -31.3% ROA vs ASBP's -13.2% |
Who Each Stock Is For
Income & stability
ASBPbeta 1.61
Growth exposure
NAUTEPS growth 16.1%
Long-term compounding (10Y)
NAUT-74.9% 10Y total return vs ASBP's -88.5%
Sleep-well-at-night portfolio
ASBPLower volatility, beta 1.61, current ratio 0.09x
Defensive / Recession hedge
ASBPBeta 1.61, current ratio 0.09x
Business Model
What each company does and how it makes money
Aspire Biopharma Holdings is a biotechnology company that develops advanced diagnostic solutions and molecular tests for disease detection. It generates revenue primarily through sales of its diagnostic assays and testing services to healthcare providers and research institutions. The company's competitive advantage lies in its proprietary genetic and biochemical research that enables high-precision disease detection capabilities.
Nautilus Biotechnology is a life sciences company developing a proteomics platform to analyze proteins at unprecedented scale and depth. It aims to generate revenue through sales of its integrated platform — including instruments, consumables, and software — though it remains pre-revenue as it develops its technology. The company's potential moat lies in its proprietary single-molecule protein analysis technology, which could enable comprehensive proteome mapping that existing methods cannot achieve.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
NAUT 2ASBP 1NAUT1/1 metricsASBP3/4 metricsNAUT5/6 metricsNAUT leads in 2 of 6 categories (Valuation Metrics, Total Returns). ASBP leads in 1 (Profitability & Efficiency). 1 tied.
Financial Metrics (TTM)
ASBP and NAUT operate at a comparable scale, with $1,941 and $0 in trailing revenue.
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $0 |
| EBITDAEarnings before interest/tax | -$28M | -$60M |
| Net IncomeAfter-tax profit | -$32M | -$63M |
| Free Cash FlowCash after capex | -$4M | -$54M |
| Gross MarginGross profit ÷ Revenue | +45.5% | — |
| Operating MarginEBIT ÷ Revenue | -10314.4% | — |
| Net MarginNet income ÷ Revenue | -16352.0% | — |
| FCF MarginFCF ÷ Revenue | -1811.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +15.4% |
Valuation Metrics
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| Market CapShares × price | $63M | $331M |
| Enterprise ValueMkt cap + debt − cash | $64M | $349M |
| Trailing P/EPrice ÷ TTM EPS | -5.08x | -5.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 2.11x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ASBP scores 2/9 vs NAUT's 1/9, reflecting mixed financial health.
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| ROE (TTM)Return on equity | — | -37.1% |
| ROA (TTM)Return on assets | -13.2% | -31.3% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | — | 0.19x |
| Net DebtTotal debt minus cash | $1M | $18M |
| Cash & Equiv.Liquid assets | $3,633 | $12M |
| Total DebtShort + long-term debt | $1M | $30M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | — |
Total Returns (with DRIP)
A $10,000 investment in NAUT five years ago would be worth $1,808 today (with dividends reinvested), compared to $1,147 for ASBP. Over the past 12 months, NAUT leads with a +118.3% total return vs ASBP's +71.4%. The 3-year compound annual growth rate (CAGR) favors NAUT at 6.8% vs ASBP's -51.4% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| YTD ReturnYear-to-date | +863.5% | +37.2% |
| 1-Year ReturnPast 12 months | +71.4% | +118.3% |
| 3-Year ReturnCumulative with dividends | -88.5% | +21.9% |
| 5-Year ReturnCumulative with dividends | -88.5% | -81.9% |
| 10-Year ReturnCumulative with dividends | -88.5% | -74.9% |
| CAGR (3Y)Annualised 3-year return | -51.4% | +6.8% |
Risk & Volatility
ASBP is the less volatile stock with a 1.61 beta — it tends to amplify market swings less than NAUT's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NAUT currently trades 85.1% from its 52-week high vs ASBP's 53.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.61x | 1.71x |
| 52-Week HighHighest price in past year | $2.45 | $3.08 |
| 52-Week LowLowest price in past year | $0.05 | $0.62 |
| % of 52W HighCurrent price vs 52-week peak | +53.9% | +85.1% |
| RSI (14)Momentum oscillator 0–100 | 41.0 | 51.4 |
| Avg Volume (50D)Average daily shares traded | 19.6M | 197K |
Analyst Outlook
| Metric | ASBPAspire Biopharma … | NAUTNautilus Biotechn… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $2.50 |
| # AnalystsCovering analysts | — | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +21.9% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jan 25 | Mar 26 | Change |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 12.6 | -87.4% |
| Nautilus Biotechnol… (NAUT) | 100 | 135.67 | +35.7% |
Nautilus Biotechnol… (NAUT) returned -82% over 5 years vs Aspire Biopharma Ho… (ASBP)'s -89%.
Chart 2Revenue Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | $0.00 | $0.00 | — |
| Nautilus Biotechnol… (NAUT) | $0.00 | $0.00 | — |
Nautilus Biotechnology, Inc.'s revenue grew from $0M (2018) to $0M (2025) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | -0.01 | -0.26 | -1900.0% |
| Nautilus Biotechnol… (NAUT) | 87.18 | -0.47 | -100.5% |
Nautilus Biotechnology, Inc.'s EPS grew from $87.18 (2018) to $-0.47 (2025) — a NaN% CAGR.
Chart 4Free Cash Flow — 5 Years
Aspire Biopharma Holdings, Inc. generated $-2M FCF in 2024 (+59% vs 2022). Nautilus Biotechnology, Inc. generated $-52M FCF in 2025 (-25% vs 2021).
ASBP vs NAUT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ASBP or NAUT a better buy right now?
Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBP or NAUT?
Over the past 5 years, Nautilus Biotechnology, Inc. (NAUT) delivered a total return of -81.9%, compared to -88.5% for Aspire Biopharma Holdings, Inc. (ASBP). A $10,000 investment in NAUT five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NAUT returned -74.9% versus ASBP's -88.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBP or NAUT?
By beta (market sensitivity over 5 years), Aspire Biopharma Holdings, Inc. (ASBP) is the lower-risk stock at 1.61β versus Nautilus Biotechnology, Inc.'s 1.71β — meaning NAUT is approximately 6% more volatile than ASBP relative to the S&P 500.
04Which has better profit margins — ASBP or NAUT?
Nautilus Biotechnology, Inc. (NAUT) is the more profitable company, earning 0.0% net margin versus -16352.0% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0.0% versus -10314.4% for ASBP. At the gross margin level — before operating expenses — ASBP leads at 45.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ASBP or NAUT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ASBP or NAUT better for a retirement portfolio?
For long-horizon retirement investors, Aspire Biopharma Holdings, Inc. (ASBP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1.71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ASBP: -88.5%, NAUT: -74.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ASBP and NAUT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.